{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:56:54Z","timestamp":1789001814323,"version":"build-2803163510"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","award":["31297"],"award-info":[{"award-number":["31297"]}],"id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005440","name":"National Institutes of Health Center for Scientific Review","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117392","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T23:18:35Z","timestamp":1759965515000},"page":"117392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"P4","title":["Antidepressants and the endogenous opioid system"],"prefix":"10.1016","volume":"242","author":[{"given":"Lloyd D.","family":"Fricker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achla","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivone","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-2874","authenticated-orcid":false,"given":"Lakshmi A.","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117392_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265928","article-title":"Antidepressants and health-related quality of life (HRQoL) for patients with depression: analysis of the medical expenditure panel survey from the United States","volume":"17","author":"Almohammed","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117392_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1472-8206.2004.00195.x","article-title":"Invited review: the evolution of antidepressant mechanisms","volume":"18","author":"Slattery","year":"2004","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0015","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2174\/138161209788168001","article-title":"Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today","volume":"15","author":"Lopez-Munoz","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2025.117392_b0020","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1176\/appi.ajp.2015.14101336","article-title":"The clinical discovery of imipramine","volume":"172","author":"Brown","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.npp.1301574","article-title":"Stress, depression, and neuroplasticity: a convergence of mechanisms","volume":"33","author":"Pittenger","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.117392_b0035","first-page":"384 p","article-title":"This is your mind on plants","author":"Pollan","year":"2021","journal-title":"Random House"},{"key":"10.1016\/j.bcp.2025.117392_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104800","article-title":"The opioid system in depression","volume":"140","author":"Jelen","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bcp.2025.117392_b0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10550880802122646","article-title":"Psychotherapeutic benefits of opioid agonist therapy","volume":"27","author":"Tenore","year":"2008","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.bcp.2025.117392_b0050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1124\/mol.120.119388","article-title":"Five decades of research on opioid peptides: current knowledge and unanswered questions","volume":"98","author":"Fricker","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0006-8993(95)00928-J","article-title":"The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores","volume":"700","author":"Mansour","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2025.117392_b0060","doi-asserted-by":"crossref","first-page":"11820","DOI":"10.1073\/pnas.2000712117","article-title":"Biased signaling by endogenous opioid peptides","volume":"117","author":"Gomes","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"963\u201376","key":"10.1016\/j.bcp.2025.117392_b0065","first-page":"e5","article-title":"A genetically encoded biosensor reveals location bias of opioid drug action","volume":"98","author":"Stoeber","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2025.117392_b0070","doi-asserted-by":"crossref","first-page":"16198","DOI":"10.1074\/jbc.RA119.008685","article-title":"Ligand-dependent spatiotemporal signaling profiles of the mu-opioid receptor are controlled by distinct protein-interaction networks","volume":"294","author":"Civciristov","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117392_b0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bcp.2016.05.014","article-title":"Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor","volume":"113","author":"Thompson","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0950","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature10954","article-title":"Crystal structure of the mu-opioid receptor bound to a morphinan antagonist","volume":"485","author":"Manglik","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117392_b0955","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature11111","article-title":"Structure of the delta-opioid receptor bound to naltrindole","volume":"485","author":"Granier","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117392_b0960","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature10939","article-title":"Structure of the human kappa-opioid receptor in complex with JDTic","volume":"485","author":"Wu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117392_b0080","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/npp.2017.60","article-title":"The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor","volume":"42","author":"Samuels","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0085","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1038\/tp.2014.30","article-title":"The atypical antidepressant and neurorestorative agent tianeptine is a mu-opioid receptor agonist","volume":"4","author":"Gassaway","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0090","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/molpharm.124.000947","article-title":"Ketamine and major ketamine metabolites function as allosteric modulators of opioid receptors","volume":"106","author":"Gomes","year":"2024","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2019.04.009","article-title":"Targeting opioid dysregulation in depression for the development of novel therapeutics","volume":"201","author":"Browne","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117392_b0100","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-022-06118-4","article-title":"Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors","author":"Wulf","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0105","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.biopsych.2022.09.020","article-title":"Opioid systems and depression: the relationship is strengthening","volume":"92","author":"Dagher","year":"2022","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0110","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1176\/ajp.149.9.1162","article-title":"Association of beta-endorphin with specific clinical symptoms of depression","volume":"149","author":"Darko","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0014-827X(99)00005-1","article-title":"Serum beta-endorphin level in patients with depression on fluvoxamine","volume":"54","author":"Djurovic","year":"1999","journal-title":"Farmaco"},{"key":"10.1016\/j.bcp.2025.117392_b0120","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1176\/ajp.138.11.1457","article-title":"Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers","volume":"138","author":"Naber","year":"1981","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0125","unstructured":"H.G. Bernstein, D. Krell, H.M. Emrich, B. Baumann, P. Danos, S. Diekmann, B. Bogerts. Fewer beta-endorphin expressing arcuate nucleus neurons and reduced beta-endorphinergic innervation of paraventricular neurons in schizophrenics and patients with depression. Cell Mol Biol (Noisy-le-grand). (2002) 48 Online Pub:OL259-65. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12643442."},{"key":"10.1016\/j.bcp.2025.117392_b0130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/mp.2014.185","article-title":"It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder","volume":"20","author":"Hsu","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0135","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41386-020-0725-9","article-title":"Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety","volume":"45","author":"Nummenmaa","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0140","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41386-021-00974-y","article-title":"Increased functional coupling of the mu opioid receptor in the anterior insula of depressed individuals","volume":"46","author":"Lutz","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/76061","article-title":"Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses","volume":"25","author":"Filliol","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2025.117392_b0155","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2025.117392_b0160","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10865-015-9628-3","article-title":"Chronic pain and comorbid mental health conditions: independent associations of posttraumatic stress disorder and depression with pain, disability, and quality of life","volume":"38","author":"Outcalt","year":"2015","journal-title":"J. Behav. Med."},{"key":"10.1016\/j.bcp.2025.117392_b0165","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/15504263.2021.1979349","article-title":"Co-occurring opioid use and depressive disorders: patient characteristics and co-occurring health conditions","volume":"17","author":"Tormohlen","year":"2021","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.bcp.2025.117392_b0170","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1021\/acschemneuro.4c00519","article-title":"Classics in chemical neuroscience: tianeptine","volume":"15","author":"Nishio","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00023210-200115030-00006","article-title":"Tianeptine: a review of its use in depressive disorders","volume":"15","author":"Wagstaff","year":"2001","journal-title":"CNS Drugs"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2025.117392_b0180","first-page":"S21","article-title":"Structure-activity relationships of tricyclic antidepressants, with special reference to tianeptine","volume":"11","author":"Labrid","year":"1988","journal-title":"Clin. Neuropharmacol."},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2025.117392_b0185","first-page":"S32","article-title":"Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase","volume":"11","author":"Mocaer","year":"1988","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-2999(00)00486-6","article-title":"Effects of acute and chronic tianeptine administration on serotonin outflow in rats: comparison with paroxetine by using in vivo microdialysis","volume":"403","author":"Malagie","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0195","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1111\/j.1460-9568.2007.05952.x","article-title":"Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine","volume":"26","author":"Svenningsson","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/mp.2009.80","article-title":"The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation","volume":"15","author":"McEwen","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0205","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.bbr.2012.05.039","article-title":"Tianeptine treatment induces antidepressive-like effects and alters BDNF and energy metabolism in the brain of rats","volume":"233","author":"Della","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bcp.2025.117392_b0210","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejphar.2007.02.023","article-title":"Tianeptine increases brain-derived neurotrophic factor expression in the rat amygdala","volume":"565","author":"Reagan","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1385\/ENDO:28:3:287","article-title":"Control of ACTH secretion by excitatory amino acids: functional significance and clinical implications","volume":"28","author":"Jezova","year":"2005","journal-title":"Endocrine"},{"key":"10.1016\/j.bcp.2025.117392_b0220","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/s41386-021-01192-2","article-title":"Mu opioid receptors on hippocampal GABAergic interneurons are critical for the antidepressant effects of tianeptine","volume":"47","author":"Han","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0225","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1186397","article-title":"Chronic tianeptine induces tolerance in analgesia and hyperlocomotion via mu-opioid receptor activation in mice","volume":"14","author":"Allain","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0230","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s00213-022-06093-w","article-title":"Opioid-like adverse effects of tianeptine in male rats and mice","volume":"239","author":"Baird","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0235","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e3182217a50","article-title":"Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers","volume":"31","author":"Bernard","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0240","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s40122-023-00539-5","article-title":"Tianeptine, an antidepressant with opioid agonist effects: pharmacology and abuse potential, a narrative review","volume":"12","author":"Edinoff","year":"2023","journal-title":"Pain Ther."},{"key":"10.1016\/j.bcp.2025.117392_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110093","article-title":"Activation of mu receptors by SR-17018 through a distinctive mechanism","volume":"258","author":"Singleton","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0250","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ddr.21228","article-title":"Comparison of antidepressant-like and abuse-related effects of phencyclidine in rats","volume":"75","author":"Hillhouse","year":"2014","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bcp.2025.117392_b0255","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2022_313","article-title":"Ketamine for depression: advances in clinical treatment, rapid antidepressant mechanisms of action, and a contrast with serotonergic psychedelics","author":"Kojic","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0260","doi-asserted-by":"crossref","first-page":"33","DOI":"10.12788\/acp.0048","article-title":"Ketamine for treatment of mood disorders and suicidality: a narrative review of recent progress","volume":"34","author":"Kritzer","year":"2022","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: a review","volume":"2","author":"Yavi","year":"2022","journal-title":"Discov. Ment. Health"},{"key":"10.1016\/j.bcp.2025.117392_b0270","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1021\/acs.jmedchem.4c02467","article-title":"Insights for the next generation of ketamine for the treatment of depressive disorder","volume":"68","author":"Faustino Martins","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117392_b0275","doi-asserted-by":"crossref","DOI":"10.1007\/s11126-025-10121-1","article-title":"Comparative efficacy and safety of ketamine versus electroconvulsive therapy in major depressive disorder: a meta-analysis of randomized controlled trials","author":"Ma","year":"2025","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.bcp.2025.117392_b0280","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/wps.20229","article-title":"What has serotonin to do with depression?","volume":"14","author":"Cowen","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0285","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pharmthera.2009.02.010","article-title":"Ketamine and the next generation of antidepressants with a rapid onset of action","volume":"123","author":"Machado-Vieira","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117392_b0290","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0295","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","article-title":"Ketamine: a tale of two enantiomers","volume":"35","author":"Jelen","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0305","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euroneuro.2021.01.005","article-title":"Comparative effects of (S)-ketamine and racemic (R\/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers","volume":"44","author":"Passie","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0310","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.4088\/JCP.17f11681","article-title":"Ketamine for depression, 3: does chirality matter?","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0315","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.bcp.2025.117392_b0320","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0325","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2025.117392_b0330","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jad.2023.02.151","article-title":"Arketamine as adjunctive therapy for treatment-resistant depression: a placebo-controlled pilot study","volume":"330","author":"Leal","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bcp.2025.117392_b0335","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117392_b0340","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12094","article-title":"Ketamine for chronic pain: risks and benefits","volume":"77","author":"Niesters","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0345","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of ketamine in the treatment of substance use disorders: a systematic review","volume":"9","author":"Jones","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0350","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.biopsych.2024.09.008","article-title":"Ketamine and hydroxynorketamine as novel pharmacotherapies for the treatment of opioid use disorders","volume":"97","author":"Onisiforou","year":"2025","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0355","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/ACO.0000000000000916","article-title":"Ketamine: a versatile tool for anesthesia and analgesia","volume":"33","author":"Barrett","year":"2020","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/j.bcp.2025.117392_b0360","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1213\/ANE.0000000000004185","article-title":"Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials","volume":"129","author":"Orhurhu","year":"2019","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.bcp.2025.117392_b0365","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.bcp.2025.117392_b0370","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2025.117392_b0375","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0380","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","article-title":"Relationship of ketamine\u2019s plasma metabolites with response, diagnosis, and side effects in major depression","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0385","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0390","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/09540261.2020.1854194","article-title":"Ketamine for depression","volume":"33","author":"Jelen","year":"2021","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0395","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1038\/s41380-022-01673-w","article-title":"Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search","volume":"27","author":"Bonaventura","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0400","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0024-3205(80)90285-4","article-title":"The interaction of ketamine with the opiate receptor","volume":"26","author":"Smith","year":"1980","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2025.117392_b0405","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00000542-198204000-00011","article-title":"Opiate receptor mediation of ketamine analgesia","volume":"56","author":"Finck","year":"1982","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2025.117392_b0410","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0773.1995.tb01041.x","article-title":"Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors","volume":"77","author":"Hustveit","year":"1995","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2025.117392_b0415","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00000542-199901000-00023","article-title":"Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells","volume":"90","author":"Hirota","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2025.117392_b0420","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s005400050035","article-title":"Interaction of ketamine with mu2 opioid receptors in SH-SY5Y human neuroblastoma cells","volume":"13","author":"Hirota","year":"1999","journal-title":"J. Anesth."},{"key":"10.1016\/j.bcp.2025.117392_b0425","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/0028-3908(87)90084-0","article-title":"Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro","volume":"26","author":"Smith","year":"1987","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172808","article-title":"Peripheral antinociception induced by ketamine is mediated by the endogenous opioid system","volume":"865","author":"Petrocchi","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0435","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","article-title":"Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism","volume":"24","author":"Williams","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0440","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0445","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.biopsych.2019.02.008","article-title":"Concurrent use of buprenorphine, methadone, or naltrexone does not inhibit ketamine\u2019s antidepressant activity","volume":"85","author":"Marton","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0450","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiat."},{"key":"10.1016\/j.bcp.2025.117392_b0455","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03800-w","article-title":"Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study","author":"Jelen","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2025.117392_b0460","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2025.117392_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173228","article-title":"Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice","volume":"208","author":"Zhang","year":"2021","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2025.117392_b0470","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41398-024-02796-0","article-title":"The endogenous opioid system in the medial prefrontal cortex mediates ketamine\u2019s antidepressant-like actions","volume":"14","author":"Jiang","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0475","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.biopsych.2018.11.006","article-title":"Lack of opioid system in the antidepressant actions of ketamine","volume":"85","author":"Zhang","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2025.04.020","article-title":"Ketamine evokes acute behavioral effects via mu-opioid receptor expressing neurons of the central amygdala","author":"Pomrenze","year":"2025","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0485","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0022-3565(25)25052-2","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat","volume":"237","author":"Yoburn","year":"1986","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2025.117392_b0490","article-title":"Mu opioid receptor activation is required for NMDA receptor antagonist effects on stress-induced maladaptive behavior","author":"Langreck","year":"2025","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0495","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0500","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1176\/appi.ajp.20240378","article-title":"Redefining ketamine pharmacology for antidepressant action: synergistic NMDA and opioid receptor interactions?","volume":"182","author":"Levinstein","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0505","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","article-title":"Potentiation of mu-opioid receptor-mediated signaling by ketamine","volume":"119","author":"Gupta","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2025.117392_b0510","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41589-020-0535-8","article-title":"TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome","volume":"16","author":"Olsen","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2025.117392_b0965","doi-asserted-by":"crossref","DOI":"10.1124\/molpharm.122.000487","article-title":"GPR83 engages endogenous peptides from two distinct precursors to elicit differential signaling","author":"Mack","year":"2022","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0515","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/bja\/57.2.197","article-title":"Comparative pharmacology of the ketamine isomers. Studies in volunteers","volume":"57","author":"White","year":"1985","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.bcp.2025.117392_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121803","article-title":"Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine","volume":"326","author":"Adzic","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2025.117392_b0525","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1021\/jm200789r","article-title":"Discovery of aminobenzyloxyarylamides as kappa opioid receptor selective antagonists: application to preclinical development of a kappa opioid receptor antagonist receptor occupancy tracer","volume":"54","author":"Mitch","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117392_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116945","article-title":"Pharmacokinetics and brain distribution of ketamine after nasal administration","volume":"264","author":"Yang","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bcp.2025.117392_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108673","article-title":"A promising chemical series of positive allosteric modulators of the mu-opioid receptor that enhance the antinociceptive efficacy of opioids but not their adverse effects","volume":"195","author":"Pryce","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0540","doi-asserted-by":"crossref","first-page":"10830","DOI":"10.1073\/pnas.1300393110","article-title":"Discovery of positive allosteric modulators and silent allosteric modulators of the mu-opioid receptor","volume":"110","author":"Burford","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2025.117392_b0545","first-page":"118","article-title":"Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects","author":"Kandasamy","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2025.117392_b0550","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0014-2999(83)90181-4","article-title":"Inhibition of enkephalin metabolism by, and antinociceptive activity of, bestatin, an aminopeptidase inhibitor","volume":"86","author":"Chaillet","year":"1983","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0555","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1021\/acschemneuro.0c00741","article-title":"Ketamine metabolite (2R,6R)-hydroxynorketamine interacts with mu and kappa opioid receptors","volume":"12","author":"Joseph","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0560","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1046648","article-title":"Suboxone: history, controversy, and open questions","volume":"13","author":"Sivils","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0565","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1476-5381.1977.tb07532.x","article-title":"Agonist and antagonist properties of buprenorphine, a new antinociceptive agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0570","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"Brown","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2025.117392_b0575","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(82)90727-9","article-title":"Antidepressant effects of buprenorphine","volume":"2","author":"Emrich","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2025.117392_b0580","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.1982.tb39483.x","article-title":"Possible antidepressive effects of opioids: action of buprenorphine","volume":"398","author":"Emrich","year":"1982","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2025.117392_b0585","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajp.2017.01.015","article-title":"Use of Buprenorphine in treatment of refractory depression-a review of current literature","volume":"26","author":"Stanciu","year":"2017","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.bcp.2025.117392_b0590","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17425255.2018.1459564","article-title":"Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder","volume":"14","author":"Ragguett","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2025.117392_b0595","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bpsgos.2021.09.003","article-title":"Low-dose augmentation with buprenorphine for treatment-resistant depression: a multisite randomized controlled trial with multimodal assessment of target engagement","volume":"2","author":"Lee","year":"2022","journal-title":"Biol. Psychiatry Glob. Open Sci."},{"key":"10.1016\/j.bcp.2025.117392_b0600","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JCP.0b013e31818638a4","article-title":"Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy","volume":"28","author":"Nyhuis","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0605","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.101679","article-title":"Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression","volume":"21","author":"Lin","year":"2019","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.bcp.2025.117392_b0615","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2147\/NDT.S199245","article-title":"Buprenorphine\/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)","volume":"15","author":"Zajecka","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.bcp.2025.117392_b0620","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","article-title":"Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial","volume":"173","author":"Fava","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0625","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41380-018-0284-1","article-title":"Opioid system modulation with buprenorphine\/samidorphan combination for major depressive disorder: two randomized controlled studies","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0630","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s13063-018-2843-9","article-title":"The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial","volume":"19","author":"Ahmadi","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.bcp.2025.117392_b0635","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ajp.2015.15040535","article-title":"Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial","volume":"173","author":"Yovell","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0640","first-page":"19","article-title":"The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review","author":"Serafini","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117392_b0645","doi-asserted-by":"crossref","first-page":"46","DOI":"10.14740\/jocmr5050","article-title":"Therapeutic potential of buprenorphine in depression: a meta-analysis of current evidence","volume":"16","author":"Bhivandkar","year":"2024","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.bcp.2025.117392_b0650","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1747-5341-3-14","article-title":"Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?","volume":"3","author":"Ioannidis","year":"2008","journal-title":"Philos. Ethics Humanit. Med."},{"key":"10.1016\/j.bcp.2025.117392_b0655","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2016.10.050","article-title":"A role for the mu opioid receptor in the antidepressant effects of buprenorphine","volume":"319","author":"Robinson","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bcp.2025.117392_b0660","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/da.22500","article-title":"Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials","volume":"33","author":"Carlezon","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.bcp.2025.117392_b0665","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/npp.2016.38","article-title":"Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors","volume":"41","author":"Falcon","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0670","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1176\/ajp.156.12.2017","article-title":"Treatment augmentation with opiates in severe and refractory major depression","volume":"156","author":"Stoll","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0675","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/JCP.0000000000001311","article-title":"Rapid improvement of treatment-resistant major depression during the administration of low-dose oxycodone","volume":"41","author":"Magen","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0680","first-page":"86","article-title":"Long-term safety and efficacy of esmethadone in patients with major depressive disorder: findings from a 12-month open-label study","author":"Fava","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0685","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41380-023-02353-z","article-title":"Unique pharmacodynamic properties and low abuse liability of the mu-opioid receptor ligand (S)-methadone","volume":"29","author":"Levinstein","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0690","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.bmcl.2014.03.040","article-title":"Antagonists of the kappa opioid receptor","volume":"24","author":"Urbano","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117392_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173341","article-title":"Enhanced antidepressant-like effects of a delta opioid receptor agonist, SNC80, in rats under inflammatory pain","volume":"214","author":"Chen","year":"2022","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.bcp.2025.117392_b0700","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/157015912803217314","article-title":"Antidepressant-like effects of delta opioid receptor agonists in animal models","volume":"10","author":"Saitoh","year":"2012","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0705","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1038\/s41467-025-57734-5","article-title":"Structure-guided design of partial agonists at an opioid receptor","volume":"16","author":"Varga","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117392_b0710","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14728214.2024.2345645","article-title":"Aticaprant: (a kappa-opioid receptor antagonist) for major depressive disorder","volume":"29","author":"Hampsey","year":"2024","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.bcp.2025.117392_b0715","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41386-024-01862-x","article-title":"Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI\/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study","volume":"49","author":"Schmidt","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0720","first-page":"18","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression","volume":"32","author":"Fava","year":"2020","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0725","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/acschemneuro.4c00541","article-title":"Structure-activity relationships and molecular pharmacology of positive allosteric modulators of the Mu-opioid receptor","volume":"16","author":"Li","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0730","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.117.109561","article-title":"Pharmacologic evidence for a putative conserved allosteric site on opioid receptors","volume":"93","author":"Livingston","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0735","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/sj.bjp.0701882","article-title":"The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds","volume":"124","author":"Gray","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0740","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.103.052613","article-title":"Evidence for an involvement of supraspinal delta- and spinal mu-opioid receptors in the antihyperalgesic effect of chronically administered clomipramine in mononeuropathic rats","volume":"307","author":"Marchand","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2025.117392_b0745","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.pbb.2006.03.022","article-title":"The involvement of endogenous opioid mechanisms in the antinociceptive effects induced by antidepressant drugs, desipramine and trimipramine","volume":"83","author":"Ozturk","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2025.117392_b0750","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ejpain.2008.01.010","article-title":"Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice","volume":"12","author":"Benbouzid","year":"2008","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.bcp.2025.117392_b0755","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.tips.2006.05.004","article-title":"Antidepressants and pain","volume":"27","author":"Mico","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2025.117392_b0760","first-page":"24","article-title":"Treatment-resistant depression (TRD): is the opioid system involved?","author":"Schreiber","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117392_b0765","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1385\/JMN:18:1-2:143","article-title":"Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects\u2013a possible opioid involvement in severe depression?","volume":"18","author":"Schreiber","year":"2002","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0770","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0014-2999(82)90241-2","article-title":"Naloxone inhibits clomipramine in mouse forced swimming test","volume":"78","author":"Devoize","year":"1982","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0775","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0091-3057(95)00067-7","article-title":"Implication of endogenous opioid system in the learned helplessness model of depression","volume":"52","author":"Tejedor-Real","year":"1995","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2025.117392_b0780","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0091-3057(99)00102-1","article-title":"Dopaminergic and opioidergic mediations of tricyclic antidepressants in the learned helplessness paradigm","volume":"64","author":"Besson","year":"1999","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2025.117392_b0785","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0006-2952(80)90531-6","article-title":"Interaction of tricyclic antidepressants with opiate receptors","volume":"29","author":"Biegon","year":"1980","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0790","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1124\/jpet.109.159939","article-title":"Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes","volume":"332","author":"Onali","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2025.117392_b0795","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1476-5381.2012.02078.x","article-title":"The atypical antidepressant mianserin exhibits agonist activity at kappa-opioid receptors","volume":"167","author":"Olianas","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0800","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0014-2999(85)90247-X","article-title":"Chronic antidepressant treatment increases enkephalin levels in n. accumbens and striatum of the rat","volume":"112","author":"De Felipe","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0805","first-page":"117","article-title":"Effect of tianeptine and fluoxetine on the levels of Met-enkephalin and mRNA encoding proenkephalin in the rat","volume":"53","author":"Dziedzicka-Wasylewska","year":"2002","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0810","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.npp.1301497","article-title":"Genetic regulation of behavioral and neuronal responses to fluoxetine","volume":"33","author":"Miller","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0815","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085136","article-title":"Global state measures of the dentate gyrus gene expression system predict antidepressant-sensitive behaviors","volume":"9","author":"Samuels","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117392_b0820","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2022.05.030","article-title":"Contribution of the opioid system to the antidepressant effects of fluoxetine","volume":"92","author":"Carazo-Arias","year":"2022","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0825","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00213-008-1232-6","article-title":"Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine","volume":"200","author":"Sillaber","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0830","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1038\/s41380-022-01725-1","article-title":"Integrative multi-omics landscape of fluoxetine action across 27 brain regions reveals global increase in energy metabolism and region-specific chromatin remodelling","volume":"27","author":"Rayan","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0835","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.1038\/tp.2015.145","article-title":"Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus","volume":"5","author":"Kroeze","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0840","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(55)92118-8","article-title":"Reserpine in the treatment of anxious and depressed patients","volume":"269","author":"Davies","year":"1955","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2025.117392_b0845","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/02698811221115762","article-title":"The effects of reserpine on depression: a systematic review","volume":"37","author":"Strawbridge","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0850","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1523\/JNEUROSCI.02-08-01150.1982","article-title":"Proportional secretion of opioid peptides and catecholamines from adrenal chromaffin cells in culture","volume":"2","author":"Wilson","year":"1982","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0855","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1073\/pnas.81.13.3949","article-title":"Alternative modes of enkephalin biosynthesis regulation by reserpine and cyclic AMP in cultured chromaffin cells","volume":"81","author":"Eiden","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2025.117392_b0860","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1124\/mol.111.072090","article-title":"Regulation of neuropeptide processing enzymes by catecholamines in endocrine cells","volume":"80","author":"Helwig","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0865","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.2009.08060852","article-title":"A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence","volume":"167","author":"Pettinati","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0870","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0306-4530(78)90013-6","article-title":"Effects of naltrexone on mood and neuroendocrine function in normal adult males","volume":"3","author":"Mendelson","year":"1978","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bcp.2025.117392_b0875","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0376-8716(81)90084-3","article-title":"Aversive effects of naltrexone in subjects not dependent on opiates","volume":"8","author":"Hollister","year":"1981","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.bcp.2025.117392_b0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172927","article-title":"R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder(1)","volume":"194","author":"Witkin","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2025.117392_b0885","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/papr.12829","article-title":"Ketamine and cognitive behavioral therapy for rapid opioid tapering with sustained opioid abstinence: a case report and 1-year follow-up","volume":"20","author":"Ocker","year":"2020","journal-title":"Pain Pract."},{"key":"10.1016\/j.bcp.2025.117392_b0890","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ejp.1317","article-title":"Intraoperative S-ketamine for the reduction of opioid consumption and pain one year after spine surgery: a randomized clinical trial of opioid-dependent patients","volume":"23","author":"Nielsen","year":"2019","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.bcp.2025.117392_b0895","first-page":"11","article-title":"Therapeutic potentials of ketamine and esketamine in obsessive-compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): a review of the current literature","author":"Martinotti","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.bcp.2025.117392_b0900","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.bcp.2025.117392_b0905","first-page":"625","article-title":"Effects of ketamine on precipitated opiate withdrawal","volume":"42","author":"Jovaisa","year":"2006","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.bcp.2025.117392_b0910","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.biopsych.2022.12.019","article-title":"Mu Opioid Receptor Activation Mediates (S)-ketamine Reinforcement in Rats: Implications for Abuse Liability","volume":"93","author":"Levinstein","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117392_b0915","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70018","article-title":"(2R,6R)-hydroxynorketamine prevents opioid abstinence-related negative affect and stress-induced reinstatement in mice","author":"Michael","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0920","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1523\/JNEUROSCI.22-03-01146.2002","article-title":"Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors","volume":"22","author":"Ghozland","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0925","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s002130000622","article-title":"Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice","volume":"154","author":"Hall","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2025.117392_b0930","doi-asserted-by":"crossref","first-page":"10935","DOI":"10.1523\/JNEUROSCI.22-24-10935.2002","article-title":"Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice","volume":"22","author":"Berrendero","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2025.117392_b0935","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00210-002-0533-2","article-title":"Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice","volume":"365","author":"Becker","year":"2002","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117392_b0940","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molbrainres.2003.10.024","article-title":"mu-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion","volume":"121","author":"Hall","year":"2004","journal-title":"Brain Res. Mol. Br Ain Res."},{"key":"10.1016\/j.bcp.2025.117392_b0945","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1038\/npp.2014.149","article-title":"Effects of genetic deletion of endogenous opioid system components on the reinstatement of cocaine-seeking behavior in mice","volume":"39","author":"Gutierrez-Cuesta","year":"2014","journal-title":"Neuropsychopharmacology"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:38:45Z","timestamp":1773178725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225006574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":193,"alternative-id":["S0006295225006574"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117392","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressants and the endogenous opioid system","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117392"}}